Quantification of pantoprazole in human plasma using LC-MS/MS for pharmacokinetics and bioequivalence study

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 35, Issue 3-4, 2011, Pages 147-155

  Li, Yun ^a   Ding, Mei Juan ^a   Ma, Jing ^a   Wang, Shu ^a   Wu, Xiao Li ^a   Xu, Hui Juan ^b   Lu, Zheng Yu ^b   Zou, Jian Jun ^c   Fan, Hong Wei ^c   Zhou, Xue Min ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Kang Enbei Pharmaceutical Co Ltd   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Bioequivalence; LC MS MS; Pantoprazole; Pharmacokinetics

Indexed keywords

OMEPRAZOLE; PANTOPRAZOLE;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CHINESE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG STABILITY; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; HUMAN EXPERIMENT; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CALIBRATION; CAPSULES; CHINA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; HUMANS; MALE; PROTON PUMP INHIBITORS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 79953797687     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-010-0018-5     Document Type: Article

References (9)

1. Cente for Drug Evaluation and Research (CDER)-Food and Drug Administration (FDA) (2002) Guidance for industry: food-effect bioavailability and fed bioequivalence studies
2. Committee for Proprietary Medicinal Products (CPMP) (1999) Note for guidance on modified release oral and transdermic dosage forms: section II (pharmacokinetic and clinical evaluation). CPMP/EWP/280/96
3. Filipe A, Almeida S, Franco Spínola AC, Neves R, Trabelsi F, Torns A et al (2008) Bioequivalence study of two entericcoated formulations of pantoprazole in healthy volunteers under fed. J Arzneimittel-Forschung (Drug Research) 58(9):451-456
4. Food and Drug Administration (FDA) (2008) Guidance on pantoprazole sodium, May 2008
5. Ling J, Wang H, Shentu JZH (2005) Determination of pantoprazole in human plasma by HPLC-MS.J. Chin J Mod Appl Pharm 22(4): 306-308
6. Osmair P, Oliveira CH, Barrientos-Astigarraga RE, Rezende VM, Mendes GD et al (2004) Determination of pantoprazole in human plasma by LC-MS-MS using lansoprazole as internal standard. J Arzneimittel-Forschung (Drug Research) 54(6): 314-319 (Pubitemid 38858241)
7. SFDA guidance for industry. Bioavailability studies for orally administered drug-products (2005) General considerations. China Department of Health and Human Services, State Food and Drug administration, Centre for Drug Evaluation and Research 2005. http://www.sfda.gov.cn/WS01/CL0001/
8. Wang LX, Li JH, Li YB (2006) Bioequivalence of pantoprazole enteric capsules in human plasma. J Clin Med Pract 10(3):30-32
9. Xu HY, Yang L, Zhang P, Shen T, Zhao HQ (2008) Determination of pantoprazole in human plasma by HPLC.J. J Shenyang Pharm Univ 25(1):44-47